Quick Answer
China SXT Pharmaceuticals, Inc. reported Diluted EPS of $2.32 per share (loss) for fiscal year 2025.
China SXT Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.32 | +91.9% |
| 2024 | -$28.58 | +83.9% |
| 2023 | -$177.84 | -28.9% |
| 2022 | -$137.92 | -3511.4% |
| 2021 | -$3.82 | -5192.0% |
| 2019 | $0.07 | +27.1% |
| 2018 | $0.06 | +0.0% |
| 2017 | $0.06 | — |
- China SXT Pharmaceuticals, Inc. showed an increase of +91.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, China SXT Pharmaceuticals, Inc.’s diluted eps has declined by 4033.9% (from $0.06 per share to $2.32 per share (loss)).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 20-F), filed with the SEC on July 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: